ZA201305946B - Diagnostic antibody assay - Google Patents
Diagnostic antibody assayInfo
- Publication number
- ZA201305946B ZA201305946B ZA2013/05946A ZA201305946A ZA201305946B ZA 201305946 B ZA201305946 B ZA 201305946B ZA 2013/05946 A ZA2013/05946 A ZA 2013/05946A ZA 201305946 A ZA201305946 A ZA 201305946A ZA 201305946 B ZA201305946 B ZA 201305946B
- Authority
- ZA
- South Africa
- Prior art keywords
- antibody assay
- diagnostic antibody
- diagnostic
- assay
- antibody
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161453449P | 2011-03-16 | 2011-03-16 | |
| PCT/EP2012/054629 WO2012123562A1 (en) | 2011-03-16 | 2012-03-16 | Diagnostic antibody assay |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201305946B true ZA201305946B (en) | 2014-10-29 |
Family
ID=45833428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2013/05946A ZA201305946B (en) | 2011-03-16 | 2013-08-07 | Diagnostic antibody assay |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8809508B2 (enExample) |
| EP (1) | EP2686346B1 (enExample) |
| JP (1) | JP6220675B2 (enExample) |
| KR (1) | KR102020072B1 (enExample) |
| CN (1) | CN103459421B (enExample) |
| AU (1) | AU2012228236B2 (enExample) |
| BR (1) | BR112013023211B1 (enExample) |
| CA (1) | CA2828433C (enExample) |
| DK (1) | DK2686346T3 (enExample) |
| EA (1) | EA032054B1 (enExample) |
| IL (1) | IL227847A0 (enExample) |
| MX (1) | MX343873B (enExample) |
| SG (1) | SG192805A1 (enExample) |
| WO (1) | WO2012123562A1 (enExample) |
| ZA (1) | ZA201305946B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6454651B2 (ja) | 2013-03-15 | 2019-01-23 | プロビオドルグ エージー | 新規阻害剤 |
| US20170363645A1 (en) | 2014-12-19 | 2017-12-21 | Probiodrug Ag | Novel Method for the Detection of pGlu-Abeta Peptides |
| EP3262070A4 (en) * | 2015-02-24 | 2018-07-25 | Rpeptide, LLC | Anti-amyloid-beta antibodies |
| CA2992386A1 (en) * | 2015-07-16 | 2017-01-19 | Probiodrug Ag | Humanized antibodies |
| GB201910697D0 (en) * | 2019-07-26 | 2019-09-11 | Binding Site Group Ltd | Lonisation control |
| KR20220066161A (ko) * | 2019-10-01 | 2022-05-23 | 리플리겐 코포레이션 | 유체의 단백질 농도 측정 |
| KR102790945B1 (ko) * | 2022-09-23 | 2025-04-04 | 경성대학교 산학협력단 | 베타-아밀로이드 42를 이용한 치매 진단 방법 및 이를 이용한 치매 진단 키트 |
| CN121253823A (zh) * | 2025-10-10 | 2026-01-02 | 山东九嘉生物科技有限公司 | 一种用于检测胃蛋白酶原ⅰ的化学发光试剂盒及其制备方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| CN101935352A (zh) * | 1999-12-08 | 2011-01-05 | 智力神经系统学公司 | 作为免疫原的嵌合肽及其抗体,以及利用嵌合肽或抗体进行免疫的方法 |
| US7117096B2 (en) * | 2001-04-17 | 2006-10-03 | Abmaxis, Inc. | Structure-based selection and affinity maturation of antibody library |
| EP1523499A2 (en) | 2002-07-24 | 2005-04-20 | Innogenetics N.V. | Fragments of beta-amyloid as targets for vaccination against alzheimer disease |
| WO2004029629A1 (en) * | 2002-09-27 | 2004-04-08 | Janssen Pharmaceutica N.V. | N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses |
| KR101099206B1 (ko) | 2004-02-05 | 2011-12-27 | 프로비오드룩 아게 | 신규한 글루타미닐 시클라제 저해제 |
| ES2259270B1 (es) | 2005-03-09 | 2007-11-01 | Consejo Superior De Investigaciones Cientificas | Metodo de diagnostico in vitro de la enfermedad de alzheimer mediante un anticuerpo monoclonal. |
| EP2043687A4 (en) | 2006-06-29 | 2010-03-17 | Centocor Ortho Biotech Inc | ANTI-AMYLOID ANTIBODIES, COMPOSITIONS, METHODS AND USES |
| US8278345B2 (en) | 2006-11-09 | 2012-10-02 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| EP2091945B1 (en) | 2006-11-09 | 2014-01-15 | Probiodrug AG | Novel inhibitors of glutaminyl cyclase |
| US7741354B2 (en) | 2006-11-09 | 2010-06-22 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| JP5523107B2 (ja) | 2006-11-30 | 2014-06-18 | プロビオドルグ エージー | グルタミニルシクラーゼの新規阻害剤 |
| US7803810B2 (en) | 2007-03-09 | 2010-09-28 | Probiodrug Ag | Inhibitors |
| DK2160389T3 (da) | 2007-04-18 | 2014-06-23 | Probiodrug Ag | Thioxoquinazolinonderivater som glutaminylcyclaseinhibitorer |
| WO2008128985A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Thiourea derivatives as glutaminyl cyclase inhibitors |
| US8227498B2 (en) | 2007-04-18 | 2012-07-24 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| WO2008128986A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Urea derivatives as glutaminyl cyclase inhibitors |
| WO2008128981A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Nitrovinyl-diamine derivatives as glutaminyl cyclase inhibitors |
| WO2008128984A1 (en) | 2007-04-20 | 2008-10-30 | Probiodrug Ag | Aminopyrimidine derivatives as glutaminyl cyclase inhibitors |
| JP2011500059A (ja) * | 2007-10-15 | 2011-01-06 | セントコア・オーソ・バイオテツク・インコーポレーテツド | ヒト抗アミロイド抗体、組成物、方法及び使用 |
| AT509611B1 (de) * | 2008-06-12 | 2012-04-15 | Affiris Forschungs-Und Entwicklungs Gmbh | Vakzin |
| EP3338795A1 (en) * | 2008-07-21 | 2018-06-27 | Probiodrug AG | Diagnostic antibody assay |
| WO2010128139A1 (en) * | 2009-05-08 | 2010-11-11 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Biomarkers and methods for diagnosing alzheimer's disease and/ or mild cognitive impairment |
| US20120100129A1 (en) * | 2009-06-29 | 2012-04-26 | Gellerfors Paer | N-Terminal Truncated Protofibrils/Oligomers for Use in Therapeutic and Diagnostic Methods for Alzheimer's Disease and Related Disorders |
-
2012
- 2012-03-16 CN CN201280013607.2A patent/CN103459421B/zh not_active Expired - Fee Related
- 2012-03-16 SG SG2013062286A patent/SG192805A1/en unknown
- 2012-03-16 EP EP12708855.7A patent/EP2686346B1/en active Active
- 2012-03-16 WO PCT/EP2012/054629 patent/WO2012123562A1/en not_active Ceased
- 2012-03-16 CA CA2828433A patent/CA2828433C/en active Active
- 2012-03-16 MX MX2013010571A patent/MX343873B/es active IP Right Grant
- 2012-03-16 KR KR1020137023118A patent/KR102020072B1/ko not_active Expired - Fee Related
- 2012-03-16 EA EA201301029A patent/EA032054B1/ru not_active IP Right Cessation
- 2012-03-16 JP JP2013558453A patent/JP6220675B2/ja not_active Expired - Fee Related
- 2012-03-16 BR BR112013023211-0A patent/BR112013023211B1/pt not_active IP Right Cessation
- 2012-03-16 US US13/422,583 patent/US8809508B2/en active Active
- 2012-03-16 AU AU2012228236A patent/AU2012228236B2/en not_active Ceased
- 2012-03-16 DK DK12708855.7T patent/DK2686346T3/en active
-
2013
- 2013-08-07 IL IL227847A patent/IL227847A0/en active IP Right Grant
- 2013-08-07 ZA ZA2013/05946A patent/ZA201305946B/en unknown
-
2014
- 2014-05-19 US US14/280,919 patent/US9657089B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR102020072B1 (ko) | 2019-11-04 |
| JP2014509860A (ja) | 2014-04-24 |
| US9657089B2 (en) | 2017-05-23 |
| EA201301029A1 (ru) | 2014-05-30 |
| CN103459421B (zh) | 2017-07-14 |
| EA032054B1 (ru) | 2019-04-30 |
| CN103459421A (zh) | 2013-12-18 |
| EP2686346A1 (en) | 2014-01-22 |
| BR112013023211B1 (pt) | 2022-11-08 |
| AU2012228236A1 (en) | 2013-10-03 |
| WO2012123562A1 (en) | 2012-09-20 |
| US20120237529A1 (en) | 2012-09-20 |
| AU2012228236B2 (en) | 2016-10-27 |
| EP2686346B1 (en) | 2016-12-14 |
| CA2828433A1 (en) | 2012-09-20 |
| US8809508B2 (en) | 2014-08-19 |
| IL227847A0 (en) | 2013-09-30 |
| MX2013010571A (es) | 2013-12-02 |
| NZ614217A (en) | 2015-12-24 |
| CA2828433C (en) | 2020-08-04 |
| JP6220675B2 (ja) | 2017-11-01 |
| MX343873B (es) | 2016-11-25 |
| KR20140006019A (ko) | 2014-01-15 |
| DK2686346T3 (en) | 2017-03-27 |
| BR112013023211A2 (pt) | 2016-11-22 |
| US20140255414A1 (en) | 2014-09-11 |
| SG192805A1 (en) | 2013-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL259826A (en) | Anti-alphabetatisiar antibody | |
| ZA201307983B (en) | Anti-b7-h3 antibody | |
| GB201103955D0 (en) | Antibodies | |
| GB201112056D0 (en) | Antibodies | |
| HUE040213T2 (hu) | Anti-TIM antitest | |
| LT3342786T (lt) | Anti-dll3 antikūnai | |
| GB201208370D0 (en) | Antibodies | |
| IL227847A0 (en) | Antibody diagnostic test | |
| TWI563004B (en) | Anti-hxcr1 antibody | |
| GB201007075D0 (en) | Diagnostic reagents | |
| PL2729809T3 (pl) | Test oznaczający | |
| GB201106615D0 (en) | Assay | |
| EP2714074A4 (en) | ANTIBODIES AGAINST EMR1 | |
| GB201102659D0 (en) | Assay | |
| GB201012072D0 (en) | Diagnostic reagents | |
| GB201121265D0 (en) | Assay | |
| GB201113101D0 (en) | Assay | |
| GB201104402D0 (en) | Diagnostic antibody assay | |
| GB201007957D0 (en) | Antibody | |
| GB201115537D0 (en) | Assay | |
| GB201115091D0 (en) | Assay | |
| GB201111608D0 (en) | Assay | |
| GB201111634D0 (en) | Assay | |
| GB201114404D0 (en) | Assay | |
| GB201107431D0 (en) | Assay |